Viridian Therapeutics, Inc. VRDN Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s operating income?
- Viridian Therapeutics, Inc. (VRDN) reported operating income of -$116.17M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s operating income changed year-over-year?
- Viridian Therapeutics, Inc.'s operating income decreased by 23.8% year-over-year, from -$93.87M to -$116.17M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s operating income has grown at a 46.1% compound annual growth rate (CAGR), from -$79.73M to -$363.4M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.